The anticholinergic and antiglutamatergic drug caramiphen reduces seizure duration in soman-exposed rats: Synergism with the benzodiazepine diazepam

Toxicology and Applied Pharmacology

Volumn 259, Issue 3, 2012, Pages 376-386

  Schultz, M K ^a   Wright, L K M ^a   Stone, M F ^a   Schwartz, J E ^a   Kelley, N R ^a   Moffett, M C ^a   Lee, R B ^a   Lumley, L A ^a  

^a US ARMY MEDICAL RESEARCH INSTITUTE OF CHEMICAL DEFENSE   (United States)

Author keywords

Caramiphen; Diazepam; Neuroprotection; Physostigmine; Seizure; Soman

Indexed keywords

ACETYLCHOLINESTERASE; CARAMIPHEN EDISYLATE; DIAZEPAM; PHYSOSTIGMINE; SOMAN;

AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY TEMPERATURE; BODY WEIGHT; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; DRUG EFFICACY; DRUG POTENTIATION; ENZYME ACTIVITY; HIPPOCAMPUS; MALE; NEUROPATHOLOGY; NONHUMAN; OUTCOME ASSESSMENT; PREPIRIFORM CORTEX; RAT; SEIZURE; THALAMUS;

ACETYLCHOLINESTERASE; ANIMALS; ANTICONVULSANTS; BODY TEMPERATURE; BODY WEIGHT; CHOLINERGIC ANTAGONISTS; CHOLINESTERASE INHIBITORS; CYCLOPENTANES; DIAZEPAM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; MALE; RATS; RATS, SPRAGUE-DAWLEY; SEIZURES; SOMAN; TIME FACTORS;

ANIMALIA; RATTUS;

EID: 84858076173     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2012.01.017     Document Type: Article

References (59)

1. Apland J.P., Braitman D.J. Effects of non-opioid antitussives on epileptiform activity and NMDA responses in hippocampal and olfactory cortex slices. Brain Res. 1990, 529:277-285.
2. Blair R.E., Sombati S., Lawrence D.C., McCay B.D., DeLorenzo R.J. Epileptogenesis causes acute and chronic increases in GABAA receptor endocytosis that contributes to the induction and maintenance of seizures in the hippocampal culture model of acquired epilepsy. J. Pharmacol. Exp. Ther. 2004, 310:871-880.
3. Cannard K. The acute treatment of nerve agent exposure. J. Neurol. Sci. 2006, 249:86-94.
4. Church J., Fletcher E.J. Blockade by sigma site ligands of high voltage-activated Ca2+ channels in rat and mouse cultured hippocampal pyramidal neurones. Br. J. Pharmacol. 1995, 116:2801-2810.
5. Churchill L., Pazdernik T.L., Jackson J.L., Nelson S.R., Samson F.E., McDonough J.H., McLeod C.G. Soman-induced brain lesions demonstrated by muscarinic receptor autoradiography. Neurotoxicology 1985, 6:81-90.
6. Churn S.B., DeLorenzo R.J. Modulation of GABAergic receptor binding by activation of calcium and calmodulin-dependent kinase II membrane phosphorylation. Brain Res. 1998, 809:68-76.
7. Clement J.G. Pharmacological nature of soman-induced hypothermia in mice. Pharmacol. Biochem. Behav. 1993, 44:689-702.
8. D'Ambrosio R., Hakimian S., Stewart T., Verley D.R., Fender J.S., Eastman C.L., Sheerin A.H., Gupta P., Diaz-Arrastia R., Ojemann J., Miller J.W. Functional definition of seizure provides new insight into post-traumatic epileptogenesis. Brain 2009, 132:2805-2821.
9. de Araujo Furtado M., Zheng A., Sedigh-Sarvestani M., Lumley L., Lichtenstein S., Yourick D. Analyzing large data sets acquired through telemetry from rats exposed to organophosphorous compounds: an EEG study. J. Neurosci. Methods 2009, 184:176-183.
10. de Araujo Furtado M., Lumley L.A., Robison C., Tong L.C., Lichtenstein S., Yourick D.L. Spontaneous recurrent seizures after status epilepticus induced by soman in Sprague-Dawley rats. Epilepsia 2010, 51:1503-1510.
11. Diana G., Scotti de Carolis A., Popoli P., Pezzola A., Sagratella S. Non-opioid antitussives potentiate some behavioural and EEG effects of N-methyl-d-aspartate channel blockers. Life Sci. 1993, 52:1547-1557.
12. Eckert S., Eyer P., Worek F. Reversible inhibition of acetylcholinesterase by carbamates or huperzine A increases residual activity of the enzyme upon soman challenge. Toxicology 2007, 233:180-186.
13. Elliot E.E., White J.M. The acute effects of zolpidem compared to diazepam and lorazepam using radiotelemetry. Neuropharmacology 2001, 40:717-721.
14. Feaster, S.R., Gordon, R.K., Doctor, B.P., 2004. Assay for detecting, measuring and monitoring the activities and concentrations of proteins and methods of use thereof Patent (US 6,746,850 B2), June 8, 2004.
15. Figueiredo T.H., Aroniadou-Anderjaska V., Qashu F., Apland J.P., Pidoplichko V., Stevens D., Ferrara T.M., Braga M.F.M. Neuroprotective efficacy of caramiphen against soman and mechanisms of action. Br. J. Pharmacol. 2011, 10.1111/j.1476-5381.2011.01427.x.
16. Fletcher E.J., Church J., Abdel-Hamid K., MacDonald J.F. Blockade by sigma site ligands of N-methyl-d-aspartate-evoked responses in rat and mouse cultured hippocampal pyramidal neurones. Br. J. Pharmacol. 1995, 116:2791-2800.
17. Gao Z.G., Liu B.Y., Cui W.Y., Li L.J., Fan Q.H., Liu C.G. Anti-nicotinic properties of anticholinergic antiparkinson drugs. J. Pharm. Pharmacol. 1998, 50:1299-1305.
18. Goodkin H.P., Yeh J.L., Kapur J. Status epilepticus increases the intracellular accumulation of GABAA receptors. J. Neurosci. 2005, 25:5511-5520.
19. Gordon J.J., Leadbeater L., Maidment M.P. The protection of animals against organophosphate poisoning by pretreatment with a carbamate. Toxicol. Appl. Pharmacol. 1978, 43:207-216.
20. Gordon R.K., Haigh J.R., Garcia G.E., Feaster S.R., Riel M.A., Lenz D.E., Aisen P.S., Doctor B.P. Oral administration of pyridostigmine bromide and huperzine A protects human whole blood cholinesterases from ex vivo exposure to soman. Chem. Biol. Interact. 2005, 157-158:239-246.
21. Haigh J.R., Lefkowitz L.J., Capacio B.R., Doctor B.P., Gordon R.K. Advantages of the WRAIR whole blood cholinesterase assay: comparative analysis to the micro-Ellman, test-mate ChE, and Michel (DeltapH) assays. Chem. Biol. Interact. 2008, 175:417-420.
22. Hudkins R.L., DeHaven-Hudkins D.L. M1 muscarinic antagonists interact with sigma recognition sites. Life Sci. 1991, 49:1229-1235.
23. Joosen M.J., Smit A.B., van Helden H.P. Treatment efficacy in a soman-poisoned guinea pig model: added value of physostigmine?. Arch. Toxicol. 2011, 85:227-237.
24. Jovanovic J.N., Thomas P., Kittler J.T., Smart T.G., Moss S.J. Brain-derived neurotrophic factor modulates fast synaptic inhibition by regulating GABA(A) receptor phosphorylation, activity, and cell-surface stability. J. Neurosci. 2004, 24:522-530.
25. Junge W., Krisch K. The carboxylesterases/amidases of mammalian liver and their possible significance. CRC Crit. Rev. Toxicol. 1975, 3:371-435.
26. Kapur J., Coulter D.A. Experimental status epilepticus alters gamma-aminobutyric acid type A receptor function in CA1 pyramidal neurons. Ann. Neurol. 1995, 38:893-900.
27. Kapur J., Lothman E.W. NMDA receptor activation mediates the loss of GABAergic inhibition induced by recurrent seizures. Epilepsy Res. 1990, 5:103-111.
28. Kassa J., Fusek J. The influence of oxime selection on the efficacy of antidotal treatment of soman-poisoned rats. Acta Medica (Hradec Kralove) 2002, 45:19-27.
29. Lallement G., Baubichon D., Clarencon D., Galonnier M., Peoc'h M., Carpentier P. Review of the value of gacyclidine (GK-11) as adjuvant medication to conventional treatments of organophosphate poisoning: primate experiments mimicking various scenarios of military or terrorist attack by soman. Neurotoxicology 1999, 20:675-684.
30. Lan J.Y., Skeberdis V.A., Jover T., Grooms S.Y., Lin Y., Araneda R.C., Zheng X., Bennett M.V., Zukin R.S. Protein kinase C modulates NMDA receptor trafficking and gating. Nat. Neurosci. 2001, 4:382-390.
31. Langston J.L., Wright L.K.M., Connis N.C., Lumley L.A. Characterizing the behavioral effects of nerve agent-induced seizure activity in rats: increased startle reactivity and preservative behavior. Pharmacol. Biochem. Behav. 2011, 10.1016/j.pbb.2011.09.011.
32. Lumley L.A., Furtado M.D., Moffett M.C., Schultz M.K., Schwartz J.E., Stone M.F., Maida D.M., Robison C.L. Ketamine and diazepam combination therapy reduces seizures, seizure associated neuropathology and functional impairment induced by soman exposure in rats. Program No. 638.14/P13. 2009 Neuroscience Meeting Planner 2009, Society for Neuroscience, Chicago, IL, Online.
33. Lynch B.A., Lambeng N., Nocka K., Kensel-Hammes P., Bajjalieh S.M., Matagne A., Fuks B. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:9861-9866.
34. Martin B.S., Kapur J. A combination of ketamine and diazepam synergistically controls refractory status epilepticus induced by cholinergic stimulation. Epilepsia 2007, 49:248-255.
35. McDonough J.H., Shih T.M. Pharmacological modulation of soman-induced seizures. Neurosci. Biobehav. Rev. 1993, 17:203-215.
36. McDonough J.H., Shih T.M. Neuropharmacological mechanisms of nerve agent-induced seizure and neuropathology. Neurosci. Biobehav. Rev. 1997, 21:559-579.
37. Meeter E., Wolthuis O.L. The effects of cholinesterase inhibitors on the body temperature of the rat. Eur. J. Pharmacol. 1968, 4:18-24.
38. Moffett M.C., Schultz M.K., Schwartz J.E., Stone M.F., Lumley L.A. Impaired auditory and contextual fear conditioning in soman-exposed rats. Pharmacol. Biochem. Behav. 2011, 98:120-129.
39. Myhrer T., Enger S., Aas P. Anticonvulsant efficacy of drugs with cholinergic and/or glutamatergic antagonism microinfused into area tempestas of rats exposed to soman. Neurochem. Res. 2008, 33:348-354.
40. Myhrer T., Enger S., Jonassen M., Aas P. Enhanced efficacy of anticonvulsants when combined with levetiracetam in soman-exposed rats. Neurotoxicology 2011, 10.1016/j.neuro.2011.04.008.
41. Naylor D.E., Liu H., Wasterlain C.G. Trafficking of GABA(A) receptors, loss of inhibition, and a mechanism for pharmacoresistance in status epilepticus. J. Neurosci. 2005, 25:7724-7733.
42. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 2005, Elsevier Academic Press, San Diego.
43. Raveh L., Chapman S., Cohen G., Alkalay D., Gilat E., Rabinovitz I., Weissman B.A. The involvement of the NMDA receptor complex in the protective effect of anticholinergic drugs against soman poisoning. Neurotoxicology 1999, 20:551-559.
44. Raveh L., Weissman B.A., Cohen G., Alkalay D., Rabinovitz I., Sonego H., Brandeis R. Caramiphen and scopolamine prevent soman-induced brain damage and cognitive dysfunction. Neurotoxicology 2002, 23:7-17.
45. Raveh L., Brandeis R., Gilat E., Cohen G., Alkalay D., Rabinovitz I., Sonego H., Weissman B.A. Anticholinergic and antiglutamatergic agents protect against soman-induced brain damage and cognitive dysfunction. Toxicol. Sci. 2003, 75:108-116.
46. Raveh L., Rabinovitz I., Gilat E., Egoz I., Kapon J., Stavitsky Z., Weissman B.A., Brandeis R. Efficacy of antidotal treatment against sarin poisoning: the superiority of benactyzine and caramiphen. Toxicol. Appl. Pharmacol. 2008, 227:155-162.
47. Shih T.M., Koviak T.A., Capacio B.R. Anticonvulsants for poisoning by the organophosphorus compound soman: pharmacological mechanisms. Neurosci. Biobehav. Rev. 1991, 15:349-362.
48. Shih T.M., Duniho S.M., McDonough J.H. Control of nerve agent-induced seizures is critical for neuroprotection and survival. Toxicol. Appl. Pharmacol. 2003, 188:69-80.
49. Sparenborg S., Brennecke L.H., Braitman D.J. Prevention of soman neurotoxicity by non-opioid antitussives. Neurotoxicology 1990, 11:509-520.
50. Szekely J.I., Sharpe L.G., Katz J.L. Effects of caramiphen and phencyclidine alone and in combination on behavior in the rat. Pharmacol. Biochem. Behav. 1994, 47:709-713.
51. Taylor P. Anticholinesterase agents. Goodman and Gilman's The Pharmacological Basis of Therapeutics 2001, 175-191. McGraw-Hill, New York. J.G. Hardman, L.E. Limbird, A.G. Gilman (Eds.).
52. Tortella F.C., Witkin J.M., Musacchio J.M. Caramiphen: a non-opioid antitussive with potent anticonvulsant properties in rats. Eur. J. Pharmacol. 1988, 155:69-75.
53. Vinkers C.H., Klanker M., Groenink L., Korte S.M., Cook J.M., Van Linn M.L., Hopkins S.C., Olivier B. Dissociating anxiolytic and sedative effects of GABAAergic drugs using temperature and locomotor responses to acute stress. Psychopharmacology (Berl) 2009, 204:299-311.
54. Wang Y., Liu L., Weiss T., Stewart C., Mikler J. Effect of acute soman exposure on GABA(A) receptors in rat hippocampal slices and cultured hippocampal neurons. Neurotox. Res. 2011, 20:334-350.
55. Wasterlain C.G., Chen J.W. Mechanistic and pharmacologic aspects of status epilepticus and its treatment with new antiepileptic drugs. Epilepsia 2008, 49:63-73.
56. Wasterlain C., Liu H., Mazarati A., Baldwin R. NMDA receptor trafficking during the transition from single seizures to status epilepticus. Ann. Neurol. 2002, 52:S16.
57. Weissman B.A., Raveh L. Therapy against organophosphate poisoning: the importance of anticholinergic drugs with antiglutamatergic properties. Toxicol. Appl. Pharmacol. 2008, 232:351-358.
58. Wetherell J., Price M., Mumford H. A novel approach for medical countermeasures to nerve agent poisoning in the guinea-pig. Neurotoxicology 2006, 27:485-491.
59. Wetherell J., Price M., Mumford H., Armstrong S., Scott L. Development of next generation medical countermeasures to nerve agent poisoning. Toxicology 2007, 233:120-127.